Abstract 6024
Background
Cancer patients are known to have higher average risk of suicide compared with general population. Acute clinical stressors, caused by deteriorating physical condition, may precipitate suicidal attempts in cancer patients.
Methods
Coroner’s files of all 4613 suicidal deaths of Hong Kong in 2012-2016 were reviewed. The files contained detailed reports on demographics, autopsy, police investigations and medical summary. Cancer was recorded in coroner’s files in 458 subjects (9.9%). Medical records of these 458 subjects were reviewed manually in a territory-wide electronic patient record system which covered 80% of all cancer care.
Results
More than half (56%) were diagnosed to have metastatic or incurable cancer at the time of suicide (advanced cancer patients). Advanced cancer patients had significantly higher health resources utilization compared with early-staged patients in terms of emergency room visit, clinic attendance and hospitalization. Emergency admissions, which represented symptom crisis, was temporally related to suicide. Ninety percent of suicide episodes occurred within 100 days of emergency admissions (median 12 days). Disclosure of bad news may represent another emotional stressor. Among advanced cancer patients, suicide occurred at a median time of 6 months after disclosure of bad news of metastases (median 182 days, interquartile range (IQR) 46-534 days). Suicide occurred at 2 months after the bad news of cessation of active cancer treatments (median 60 days, IQR 24-196 days). For psychiatric risk factors, advanced cancer patients had lower rate of psychiatric diagnosis compared with early-staged cancer patients (12.5% vs 23.7% p = 0.003). Similar trend was observed in other factors including gambling, debt and history of self-harm (2.3% vs 0.0%, p = 0.03; 2.8% vs 0.3%, p = 0.02; 4.4% vs 1.3%, p = 0.08 respectively).
Conclusions
Emergency admissions and bad news disclosure represent acute stressors that may precipitate suicidal attempts in cancer patients. Such temporal relationship was particularly strong in advanced cancer patients, suggesting a critical window for suicidal prevention interventions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The Hong Kong Jockey Club, Li Ka Shing Foundation.
Disclosure
T.C. Lam: Research grant / Funding (self): Roche; Research grant / Funding (self): Mundipharma. All other authors have declared no conflicts of interest.
Resources from the same session
2413 - Implementation of PRO-CTCAE in phase I clinical trials identifies under reporting of adverse events
Presenter: Zachary Veitch
Session: Poster Discussion – Supportive and palliative care
Resources:
Abstract
5816 - The ImmunoTOX multidisciplinary board, a descriptive study of collaborative management of immune-related adverse events.
Presenter: Jean-Marie Michot
Session: Poster Discussion – Supportive and palliative care
Resources:
Abstract
3064 - Development of GOLD (Geriatric Oncology Liaison Development) service to improve outcomes in older people with cancer
Presenter: Matthaios Kapiris
Session: Poster Discussion – Supportive and palliative care
Resources:
Abstract
3627 - Complementary Medicine (CM) Use in Phase III Clinical Trials (P3T) Conducted by the Canadian Cancer Trials Group (CCTG)
Presenter: John Wells
Session: Poster Discussion – Supportive and palliative care
Resources:
Abstract
5591 - Worse Patient- Physician Relationship Is Associated With More Fear Of Cancer Recurrence (Deimos Study): A Study Of The Palliative Care Working Committee Of The Turkish Oncology Group (TOG)
Presenter: Ali Alkan
Session: Poster Discussion – Supportive and palliative care
Resources:
Abstract
7257 - Can tocotrienol reduce time to the first serious adverse event during treatment with FOLFOXIRI for colorectal cancer?
Presenter: Louise Raunkilde
Session: Poster Discussion – Supportive and palliative care
Resources:
Abstract
1647 - Primary analysis results of randomized controlled trial evaluating reactive topical corticosteroid strategies for the facial acneiform rash by EGFR inhibitors (EGFRIs) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) -FAEISS study-
Presenter: Naoya Yamazaki
Session: Poster Discussion – Supportive and palliative care
Resources:
Abstract
Poster Discussion – Supportive and palliative care - Invited Discussant 1755PD, 1756PD and 1757PD
Presenter: Paolo Bossi
Session: Poster Discussion – Supportive and palliative care
Resources:
Slides
Webcast
Poster Discussion – Supportive and palliative care - Invited Discussant LBA37, LBA90 and 1758PD
Presenter: Anton Snegovoy
Session: Poster Discussion – Supportive and palliative care
Resources:
Slides
Webcast
Poster Discussion – Supportive and palliative care - Invited Discussant 1597PD and 1617PD
Presenter: Stein Kaasa
Session: Poster Discussion – Supportive and palliative care
Resources:
Slides
Webcast